Sara Kuruvilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sara Kuruvilla has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- David Anthony Palma
Department of Radiation Oncology, London Health Sciences Centre, Western University, London, Canada
6 shared publications - Anthony Charles Nichols
Department of Otolaryngology—Head and Neck Surgery, Western University, London, ON, Canada
5 shared publications - Eric Winquist
Division of Medical Oncology, Department of Oncology, Western University, London, ON, Canada
5 shared publications - Julie. A. Theurer
School of Communication Sciences and Disorders, Western University, London, ON, Canada
4 shared publications - Kevin Fung
Department of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, Canada
4 shared publications - Nancy Read
Division of Radiation Oncology, London Health Sciences Centre, 800 Commissioners Rd. E, London, ON, N6A 5W9, Canada
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Neoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study
Purpose: PIK3CA -activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negative head and neck squamous cell carcinomas (HNSCCs). PI3K pathway inhibition is postulated as a potential therapeutic strategy, and preclinical studies have demonstrated that the PI3Kα selective inhibitor alpelisib has broad tumoristatic activity across HNSCC genotypes. Methods: In this trial, patients with oral cavity HNSCC received either 400 mg or 200 mg of alpelisib once daily for up to 14 days preoperatively. The primary end point was the change in phosphorylated S6 (Ser235/236) expression in paired pre- and post-treatment tumor samples as assessed by immunohistochemistry. Secondary end points included changes in tumor size, pathologic response, phospho-AKT, Ki-67, and transcriptome differences between baseline and post-treatment tumor samples, as well as associations between baseline genomic variants and tumor response. Results: Of the 15 patients enrolled, 14 completed the treatment. The first five patients received a dose of 400 mg once daily; however, three of five patients experienced grade 3 hypertension, fatigue, and oral mucositis; thus, the protocol was amended with a lower dose of 200 mg for the subsequent 10 patients. Pre- and post-treatment tumor samples were available for 13 patients. Of the 13 patients analyzed, eight patients had decreased levels of phosphorylated S6 serine 235/236, whereas three patients had no change and two patients had increased levels. Two clinical partial responses as per RECIST 1.1 were observed (13.3%); however, there were no pathological responses. Molecular profiling revealed seven patients had PIK3CA amplification, and no patients had PIK3CA point mutations. NanoString analysis demonstrated that alpelisib induced tumor transcriptome changes, including decreases in SPP1 transcript abundance. Conclusion: Preoperative alpelisib achieved a 13.3% response rate, reduced phospho-S6 Ser235/236 levels in eight of 13 patients, and induced tumor transcriptomic changes.
- 1 October 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- Vol. 3 (4)
Open AccessNeoadjuvant PIK3CA Inhibition With Alpelisib in Head and Neck Squamous Cell Cancer: A Window-of-Opportunity Trial and Biomarker Study
Purpose: PIK3CA -activating mutations and amplifications are common in both human papillomavirus (HPV)–positive and HPV-negative head and neck squamous cell carcinomas (HNSCCs). PI3K pathway inhibition is postulated as a potential therapeutic strategy, and preclinical studies have demonstrated that the PI3Kα selective inhibitor alpelisib has broad tumoristatic activity across HNSCC genotypes. Methods: In this trial, patients with oral cavity HNSCC received either 400 mg or 200 mg of alpelisib once daily for up to 14 days preoperatively. The primary end point was the change in phosphorylated S6 (Ser235/236) expression in paired pre- and post-treatment tumor samples as assessed by immunohistochemistry. Secondary end points included changes in tumor size, pathologic response, phospho-AKT, Ki-67, and transcriptome differences between baseline and post-treatment tumor samples, as well as associations between baseline genomic variants and tumor response. Results: Of the 15 patients enrolled, 14 completed the treatment. The first five patients received a dose of 400 mg once daily; however, three of five patients experienced grade 3 hypertension, fatigue, and oral mucositis; thus, the protocol was amended with a lower dose of 200 mg for the subsequent 10 patients. Pre- and post-treatment tumor samples were available for 13 patients. Of the 13 patients analyzed, eight patients had decreased levels of phosphorylated S6 serine 235/236, whereas three patients had no change and two patients had increased levels. Two clinical partial responses as per RECIST 1.1 were observed (13.3%); however, there were no pathological responses. Molecular profiling revealed seven patients had PIK3CA amplification, and no patients had PIK3CA point mutations. NanoString analysis demonstrated that alpelisib induced tumor transcriptome changes, including decreases in SPP1 transcript abundance. Conclusion: Preoperative alpelisib achieved a 13.3% response rate, reduced phospho-S6 Ser235/236 levels in eight of 13 patients, and induced tumor transcriptomic changes.
- 29 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26)
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix I and Appendix II ). Updates are published regularly and can be found on the ASCO Publications website .
- 29 June 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (26)
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2
Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating clinician and do not account for individual variation among patients. See appendix for disclaimers and other important information ( Appendix I and Appendix II ). Updates are published regularly and can be found on the ASCO Publications website .
- Top Cited Papers
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (7) , JCO2502822
Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (7) , JCO2502822
Top Cited PapersTherapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature, and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer with driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Thirteen studies were identified in the latest search of literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients with driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
- Top Cited Papers
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (7) , JCO2502825
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (7) , JCO2502825
Top Cited PapersTherapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases, or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more . PURPOSE: To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS: This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized controlled trials (RCTs), with the latest time frame spanning March-October 2025. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts was convened. The literature search included systematic reviews, meta-analyses, and RCTs. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Six new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS: Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/thoracic-cancer-guidelines .
- Open Access
- 19 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108840
Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
- 19 November 2025
- Published by Elsevier in Lung Cancer
- Vol. 210, 108840
Open AccessTreatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)
- Open Access
- 19 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 366
A Neuropsychiatric Prelude to Unveiling Small Cell Lung Cancer with Suspected Paraneoplastic Limbic Encephalitis: A Case Report
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by rapid growth and early metastases. As a neuroendocrine tumour, SCLC is especially notorious for various paraneoplastic syndromes, one of which is a rare neurological syndrome called paraneoplastic limbic encephalitis (PLE) that manifests with amnestic cognitive impairment and seizures. Here, we describe a case of a 53-year-old female who presented with neuropsychiatric symptoms of delusions, hallucinations, and cognitive impairment that started months prior to being diagnosed with extensive-stage SCLC. With no previous neuropsychiatric history, this raised the question of whether her presentation was related to PLE rather than a primary psychiatric condition, as initially diagnosed. Her symptoms improved with chemotherapy and radiation treatment of the underlying cancer, favouring a paraneoplastic etiology. Overall, this case underscores the importance of considering paraneoplastic syndromes in patients presenting with new neuropsychiatric symptoms, as early recognition and treatment can improve prognosis.
- 19 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 366
Open AccessA Neuropsychiatric Prelude to Unveiling Small Cell Lung Cancer with Suspected Paraneoplastic Limbic Encephalitis: A Case Report
Small cell lung cancer (SCLC) is an aggressive form of lung cancer characterized by rapid growth and early metastases. As a neuroendocrine tumour, SCLC is especially notorious for various paraneoplastic syndromes, one of which is a rare neurological syndrome called paraneoplastic limbic encephalitis (PLE) that manifests with amnestic cognitive impairment and seizures. Here, we describe a case of a 53-year-old female who presented with neuropsychiatric symptoms of delusions, hallucinations, and cognitive impairment that started months prior to being diagnosed with extensive-stage SCLC. With no previous neuropsychiatric history, this raised the question of whether her presentation was related to PLE rather than a primary psychiatric condition, as initially diagnosed. Her symptoms improved with chemotherapy and radiation treatment of the underlying cancer, favouring a paraneoplastic etiology. Overall, this case underscores the importance of considering paraneoplastic syndromes in patients presenting with new neuropsychiatric symptoms, as early recognition and treatment can improve prognosis.
- Open Access
- 31 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6735-6748
Programmed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study
Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes among patients with resected stage IB-IIIA NSCLC tumors expressing PD-L1 using PALEOS (Pan-cAnadian Lung cancEr Observational Study) data (2016–2019). Key outcomes included PD-L1 expression rate and treatment patterns, recurrence, and median overall (mOS) and disease-free survival (mDFS) among PD-L1+ patients. Among 539 PD-L1–tested patients, 317 (58.8%) were PD-L1+ (≥1%). At diagnosis, 35.3%, 39.8%, and 24.9% of PD-L1+ patients had stage IB, II, or IIIA disease. Forty-one percent had received adjuvant therapy. At 22.6 months (median follow-up), first disease recurrence had occurred in 31.9% of patients, primarily at metastatic sites. After first metastatic recurrence, ICI regimens were the most common first systemic therapy (29.8%). mOS was not reached; mDFS was 40.0 months. At four years, DFS probability was 44%. Four-year OS and DFS rates were generally similar when stratified by PD-L1 expression (1–49% vs. ≥50%). These findings underscore the generally poor outcomes experienced by patients with early-stage, resected, PD-L1+ NSCLC after treatment with available adjuvant therapies, and provide context to recent and emerging trials of new treatment options.
- 31 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6735-6748
Open AccessProgrammed Cell Death-Ligand 1 Expression and Clinical Outcomes Among Patients with Resected, Early-Stage Non-Small Cell Lung Cancer: A Real-World Study
Treatment options for non-small cell lung cancer (NSCLC) are evolving, given recent and expected approvals of immune checkpoint inhibitors (ICIs) targeting programmed cell death-(ligand) 1 (PD-1/PD-L1). We retrospectively evaluated outcomes among patients with resected stage IB-IIIA NSCLC tumors expressing PD-L1 using PALEOS (Pan-cAnadian Lung cancEr Observational Study) data (2016–2019). Key outcomes included PD-L1 expression rate and treatment patterns, recurrence, and median overall (mOS) and disease-free survival (mDFS) among PD-L1+ patients. Among 539 PD-L1–tested patients, 317 (58.8%) were PD-L1+ (≥1%). At diagnosis, 35.3%, 39.8%, and 24.9% of PD-L1+ patients had stage IB, II, or IIIA disease. Forty-one percent had received adjuvant therapy. At 22.6 months (median follow-up), first disease recurrence had occurred in 31.9% of patients, primarily at metastatic sites. After first metastatic recurrence, ICI regimens were the most common first systemic therapy (29.8%). mOS was not reached; mDFS was 40.0 months. At four years, DFS probability was 44%. Four-year OS and DFS rates were generally similar when stratified by PD-L1 expression (1–49% vs. ≥50%). These findings underscore the generally poor outcomes experienced by patients with early-stage, resected, PD-L1+ NSCLC after treatment with available adjuvant therapies, and provide context to recent and emerging trials of new treatment options.
- 12 September 2022
- Published by Elsevier in Lung Cancer
- Vol. 173, 58-66
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
- 12 September 2022
- Published by Elsevier in Lung Cancer
- Vol. 173, 58-66
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
- Open Access
- 29 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24602
A Case of Li-Fraumeni Associated Thymoma
Thymomas are among the most common cancers of the anterior mediastinum. They rarely occur in patients with Li-Fraumeni syndrome (LFS), a hereditary syndrome that predisposes individuals to cancer and is characterized by mutations in the tumor suppressor encoding gene TP53. Here we describe a case of primary thymoma in a woman diagnosed with LFS. We cover the initial presentation and diagnosis, radiological findings, histopathological examination, and management of thymoma. In addition, we review p53 physiology and LFS pathophysiology to explore how TP53 expression might differ between the majority of thymomas and in thymomas associated with LFS. This altered pathophysiology may affect management and prognosis due to emerging evidence of increased resistance to conventional treatment, which suggests a need for close monitoring and consideration of novel treatment strategies such as programmed death-ligand 1 (PD-L1) inhibitors.
- 29 April 2022
- Published by Springer Nature in Cureus
- Vol. 14 (4) , e24602
Open AccessA Case of Li-Fraumeni Associated Thymoma
Thymomas are among the most common cancers of the anterior mediastinum. They rarely occur in patients with Li-Fraumeni syndrome (LFS), a hereditary syndrome that predisposes individuals to cancer and is characterized by mutations in the tumor suppressor encoding gene TP53. Here we describe a case of primary thymoma in a woman diagnosed with LFS. We cover the initial presentation and diagnosis, radiological findings, histopathological examination, and management of thymoma. In addition, we review p53 physiology and LFS pathophysiology to explore how TP53 expression might differ between the majority of thymomas and in thymomas associated with LFS. This altered pathophysiology may affect management and prognosis due to emerging evidence of increased resistance to conventional treatment, which suggests a need for close monitoring and consideration of novel treatment strategies such as programmed death-ligand 1 (PD-L1) inhibitors.
- Open Access
- 1 December 2021
- Published by AME Publishing Company in Mediastinum
- Vol. 5, AB014
AB014. A case of Li-Fraumeni syndrome associated thymoma
Li-Fraumeni syndrome (LFS) is a rare genetic cancer syndrome caused by loss of function mutations of the tumor suppressor gene TP53. We present a case of LFS associated thymoma, a very rare occurrence in the population of LFS patients. A 57-year-old woman presented to the emergency room with swelling in her neck, face and right arm. The patient had no previous personal history of cancer but family history was significant and genetic consultation had revealed a missense mutation of TP53. Chest X-ray showed a large superior mediastinal mass. A CT scan confirmed an aggressive anterior mediastinal mass overlying the sternum and anterior left pleural space. It invaded and obstructed the superior vena cava and left brachiocephalic vein. Enlarged mediastinal lymph nodes and a small pericardial effusion was evident. Pathology on core needle biopsy of the mass revealed a thymoma consisting of large, atypical epithelial cells with admixed background thymocytes and intersecting dense, fibrous bands. The level of atypia was unusual, with cells showing pleomorphic nuclei with a high nuclear to cytoplasmic ratio. Immunohistochemistry was performed for the p53 protein. The malignant epithelial cells stained with strong nuclear positivity, however, there was no staining of background normal cells. The patient was treated with radiation and 6 cycles of Cisplatin-Etoposide chemotherapy with reduction in the size of the primary mass, mediastinal lymph nodes and pericardial effusion. Treatment relieved symptoms but her disease remained unresectable. Patient presentation, genetic consultation and pathological analysis was consistent with LFS associated thymoma. Due to the degree of atypia, the final diagnosis was thymoma with anaplasia. This case demonstrates that thymoma can be a rare consequence of LFS and must be assessed for when appropriate. Prior research shows sporadic p53 mutated thymoma is rare, however the mutation carries a worse prognosis and it is unknown what the implications are for the LPS population. The pathological findings of elevated p53 levels in the context of LFS is intriguing and may be a target of future research.
- 1 December 2021
- Published by AME Publishing Company in Mediastinum
- Vol. 5, AB014
Open AccessAB014. A case of Li-Fraumeni syndrome associated thymoma
Li-Fraumeni syndrome (LFS) is a rare genetic cancer syndrome caused by loss of function mutations of the tumor suppressor gene TP53. We present a case of LFS associated thymoma, a very rare occurrence in the population of LFS patients. A 57-year-old woman presented to the emergency room with swelling in her neck, face and right arm. The patient had no previous personal history of cancer but family history was significant and genetic consultation had revealed a missense mutation of TP53. Chest X-ray showed a large superior mediastinal mass. A CT scan confirmed an aggressive anterior mediastinal mass overlying the sternum and anterior left pleural space. It invaded and obstructed the superior vena cava and left brachiocephalic vein. Enlarged mediastinal lymph nodes and a small pericardial effusion was evident. Pathology on core needle biopsy of the mass revealed a thymoma consisting of large, atypical epithelial cells with admixed background thymocytes and intersecting dense, fibrous bands. The level of atypia was unusual, with cells showing pleomorphic nuclei with a high nuclear to cytoplasmic ratio. Immunohistochemistry was performed for the p53 protein. The malignant epithelial cells stained with strong nuclear positivity, however, there was no staining of background normal cells. The patient was treated with radiation and 6 cycles of Cisplatin-Etoposide chemotherapy with reduction in the size of the primary mass, mediastinal lymph nodes and pericardial effusion. Treatment relieved symptoms but her disease remained unresectable. Patient presentation, genetic consultation and pathological analysis was consistent with LFS associated thymoma. Due to the degree of atypia, the final diagnosis was thymoma with anaplasia. This case demonstrates that thymoma can be a rare consequence of LFS and must be assessed for when appropriate. Prior research shows sporadic p53 mutated thymoma is rare, however the mutation carries a worse prognosis and it is unknown what the implications are for the LPS population. The pathological findings of elevated p53 levels in the context of LFS is intriguing and may be a target of future research.